Fosun's revised Gland takeover plan no longer needs Indian approval

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Pharmaceutical drug, Pharmacology

Shanghai Fosun Pharma says it no longer requires the Indian Government's permission to buy a majority stake in Gland Pharma.

In an emailed statement Fosun told us it will buy 74% stake in Gland for $ 1.1bn (€912.6bn) and set a termination date for the deal of October 3.

The Hong Kong Stock Exchange listed firm said: “The stake of Gland Pharma held by KKR Floorline Investment Pte. Ltd. and the Founder Shareholders that will be acquired by Fosun Pharma is adjusted from 69.971% to 57.891%​.”

After the transaction is completed, KKR will no longer own shares in Gland Pharma​.”

Government approval

Fosun announced its intention to buy Gland from founders and US investment group KKR in July​ last year, originally stateing that it would acquire an 86% stake in the Indian firm.

In August​ this year Fosun said India’s Foreign Investment Promotion Board (FIPB) had referred the takeover plan to the Government’s Cabinet Committee on Economic Affairs for review.

At the time a Fosun spokeswoman told us “The acquisition obtained prior approval from relevant PRC [People’s Republic of China] authorities, and is pending review and approval from the Cabinet Committee on Economic Affairs of India.”

Under rules​ introduced this year, any foreign investor that wants to buy an Indian drug manufacturer needs to seek Government approval if it plans to buy more that 74% of the target company's shares.

API supply

Gland makes injectable drugs, both own-brand medicines and for other firms on a contractual basis. It operates four facilities in India that produce active pharmaceutical ingredients (API) and finished dosage formulations.

The firm is a major supplier of the API heparin to hospitals in India.

Related news

Show more

Related products

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers